15.66
price down icon1.88%   -0.30
after-market Handel nachbörslich: 15.66
loading
Schlusskurs vom Vortag:
$15.96
Offen:
$15.92
24-Stunden-Volumen:
942.76K
Relative Volume:
0.52
Marktkapitalisierung:
$2.34B
Einnahmen:
$181.74M
Nettoeinkommen (Verlust:
$-143.97M
KGV:
-11.27
EPS:
-1.39
Netto-Cashflow:
$9.60M
1W Leistung:
+0.26%
1M Leistung:
+3.50%
6M Leistung:
-20.22%
1J Leistung:
-41.72%
1-Tages-Spanne:
Value
$15.33
$16.11
1-Wochen-Bereich:
Value
$14.93
$16.11
52-Wochen-Spanne:
Value
$9.57
$30.41

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Name
Firmenname
Arrowhead Pharmaceuticals Inc
Name
Telefon
626-696-4702
Name
Adresse
177 E COLORADO BLVD, PASADENA, CA
Name
Mitarbeiter
609
Name
Nächster Verdiensttermin
2025-02-10
Name
Neueste SEC-Einreichungen
Name
ARWR's Discussions on Twitter

Vergleichen Sie ARWR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ARWR
Arrowhead Pharmaceuticals Inc
15.66 2.34B 181.74M -143.97M 9.60M -1.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.82 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
520.29 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
321.94 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.53 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
267.12 28.51B 3.81B -644.79M -669.77M -6.24

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-06-05 Eingeleitet Goldman Neutral
2023-12-04 Eingeleitet BofA Securities Buy
2023-09-19 Eingeleitet Citigroup Neutral
2023-07-21 Eingeleitet TD Cowen Outperform
2023-05-12 Herabstufung SVB Securities Outperform → Market Perform
2023-04-26 Eingeleitet SMBC Nikko Outperform
2023-04-12 Hochstufung SVB Securities Market Perform → Outperform
2023-03-21 Eingeleitet Bernstein Mkt Perform
2022-09-09 Eingeleitet Morgan Stanley Equal-Weight
2022-05-11 Hochstufung Robert W. Baird Neutral → Outperform
2022-01-19 Fortgesetzt Goldman Buy
2021-08-06 Bestätigt Chardan Capital Markets Buy
2021-06-04 Fortgesetzt Robert W. Baird Neutral
2021-02-05 Bestätigt H.C. Wainwright Buy
2020-12-21 Herabstufung Robert W. Baird Outperform → Neutral
2020-12-16 Eingeleitet UBS Buy
2020-11-19 Eingeleitet Citigroup Buy
2020-05-13 Eingeleitet RBC Capital Mkts Outperform
2020-05-08 Hochstufung Oppenheimer Perform → Outperform
2020-04-15 Hochstufung Cantor Fitzgerald Neutral → Overweight
2020-03-24 Hochstufung SVB Leerink Underperform → Mkt Perform
2020-03-17 Eingeleitet Goldman Neutral
2020-01-21 Eingeleitet SVB Leerink Underperform
2019-12-13 Eingeleitet Oppenheimer Perform
2019-11-29 Bestätigt Chardan Capital Markets Buy
2019-11-27 Bestätigt B. Riley FBR Buy
2019-11-25 Hochstufung Robert W. Baird Neutral → Outperform
2019-10-24 Herabstufung Robert W. Baird Outperform → Neutral
2019-10-22 Bestätigt Chardan Capital Markets Buy
2019-10-03 Eingeleitet Robert W. Baird Outperform
2018-09-07 Hochstufung B. Riley FBR Neutral → Buy
2018-09-06 Bestätigt Chardan Capital Markets Buy
2018-08-08 Bestätigt Cantor Fitzgerald Overweight
2018-07-02 Bestätigt Chardan Capital Markets Buy
Alle ansehen

Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten

pulisher
Jun 12, 2025

Where are the Opportunities in (ARWR) - news.stocktradersdaily.com

Jun 12, 2025
pulisher
Jun 12, 2025

Homozygous Familial Hypercholesterolemia Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics, Amryt Pharma - The Globe and Mail

Jun 12, 2025
pulisher
Jun 12, 2025

GAMMA Investing LLC Increases Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald Weighs in on ARWR FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 10, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Arrowhead Pharmaceuticals at Goldman Sachs Conference: Strategic Launch Plans By Investing.com - Investing.com Canada

Jun 09, 2025
pulisher
Jun 08, 2025

California State Teachers Retirement System Reduces Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to “Buy” at Wall Street Zen - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money” - Insider Monkey

Jun 05, 2025
pulisher
Jun 04, 2025

Arrowhead at Jefferies Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada

Jun 04, 2025
pulisher
Jun 04, 2025

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses' - Benzinga

Jun 04, 2025
pulisher
Jun 02, 2025

Arrowhead (ARWR) Kicks Off Clinical Trial for Obesity Treatment ARO-ALK7 | ARWR Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a Study - Insider Monkey

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - BioSpace

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2A Study Of Aro-Alk7 For The Treatment Of Obesity - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity | ARWR Stock News - GuruFocus

Jun 02, 2025
pulisher
May 31, 2025

(ARWR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

May 31, 2025
pulisher
May 30, 2025

SA analyst downgrades: PLTR, PSTG, NTLA, ARWR - Seeking Alpha

May 30, 2025
pulisher
May 29, 2025

Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade) (ARWR) - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Arrowhead Pharmaceuticals to Participate in June 2025 Investor C - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Arrowhead (ARWR) Skyrockets Over 5.7%: Can This Biotech Breakout Propel It Towards $20? - Daily Chhattisgarh News

May 29, 2025
pulisher
May 29, 2025

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences - BioSpace

May 29, 2025
pulisher
May 24, 2025

Arrowhead Pharmaceuticals’ SWOT analysis: RNAi pioneer nears first approval - Investing.com

May 24, 2025
pulisher
May 23, 2025

What is HC Wainwright’s Estimate for ARWR FY2025 Earnings? - Defense World

May 23, 2025
pulisher
May 22, 2025

HC Wainwright Reiterates Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - Defense World

May 22, 2025
pulisher
May 21, 2025

Arrowhead at RBC Conference: Strategic Insights on Drug Pipeline By Investing.com - Investing.com India

May 21, 2025
pulisher
May 20, 2025

Arrowhead Pharma (ARWR) Receives Reiterated Buy Rating from HC Wainwright | ARWR Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

BNP Paribas Financial Markets Acquires 32,841 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

May 19, 2025
pulisher
May 18, 2025

Research Analysts Offer Predictions for ARWR FY2025 Earnings - Defense World

May 18, 2025
pulisher
May 18, 2025

B. Riley Brokers Boost Earnings Estimates for ARWR - Defense World

May 18, 2025
pulisher
May 17, 2025

Dimensional Fund Advisors LP Sells 86,214 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

May 17, 2025
pulisher
May 17, 2025

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at StockNews.com - Defense World

May 17, 2025
pulisher
May 16, 2025

ARWR: Multiple Value Drivers for Long-Term Growth - Research Tree

May 16, 2025
pulisher
May 16, 2025

Q3 Earnings Forecast for ARWR Issued By Leerink Partnrs - Defense World

May 16, 2025
pulisher
May 16, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World

May 16, 2025
pulisher
May 15, 2025

Arrowhead Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks

May 15, 2025
pulisher
May 15, 2025

Arrowhead targets 2025 plozasiran launch with $1.1B cash and clinical pipeline momentum - MSN

May 15, 2025
pulisher
May 15, 2025

ARWR July 18th Options Begin Trading - Nasdaq

May 15, 2025
pulisher
May 15, 2025

ARWR: Multiple Value Drivers for Long-Term Growth… - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Citigroup Lowers Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $17.00 - Defense World

May 15, 2025
pulisher
May 14, 2025

UBS Adjusts Price Target for Arrowhead (ARWR) While Maintaining Buy Rating | ARWR Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $63 From $71, Maintains Buy Rating - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025
pulisher
May 14, 2025

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st

May 14, 2025
pulisher
May 14, 2025

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Up on Earnings Beat - Defense World

May 14, 2025
pulisher
May 14, 2025

Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR St - GuruFocus

May 14, 2025
pulisher
May 13, 2025

RBC cuts Arrowhead Pharma target to $40; keeps Outperform By Investing.com - Investing.com Canada

May 13, 2025
pulisher
May 13, 2025

Arrowhead Pharma (ARWR) Maintains Neutral Rating but Faces Price Target Cut | ARWR Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Arrowhead Pharma (ARWR) Maintains Buy Rating with $60 Price Targ - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

RBC Adjusts Price Target on Arrowhead Pharmaceuticals to $40 From $42, Maintains Outperform Speculative Risk Rating - marketscreener.com

May 13, 2025

Finanzdaten der Arrowhead Pharmaceuticals Inc-Aktie (ARWR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Arrowhead Pharmaceuticals Inc-Aktie (ARWR) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Anzalone Christopher Richard
Chief Executive Officer
Apr 10 '25
Sale
10.87
50,000
543,500
3,972,055
Anzalone Christopher Richard
Chief Executive Officer
Apr 09 '25
Sale
10.07
40,322
406,145
4,022,055
$20.52
price down icon 1.06%
$35.91
price down icon 0.64%
$21.27
price up icon 1.67%
$104.85
price down icon 0.99%
$104.80
price down icon 0.28%
biotechnology ONC
$267.12
price up icon 0.12%
Kapitalisierung:     |  Volumen (24h):